Sign In
Buy CPRX
$31.49
+0 (+0%)
At Close: Jul 31, 2026
Catalyst Pharmaceutical (CPRX) Surpasses Q1 Earnings Estimates
08:17pm, Monday, 10'th May 2021
Catalyst (CPRX) delivered earnings and revenue surprises of 22.22% and -6.01%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Catalyst Pharmaceuticals Announces First Quarter 2021 Financial Results and Provides Business Update
05:29pm, Monday, 10'th May 2021
-Firdapse® Q1 2021 Net Revenues of $30.2 Million
This Under-the-Radar Pharma Company's Recent Success Is Just the Beginning
06:12am, Saturday, 08'th May 2021
Catalyst is facing its fair share of classic pharma challenges.
Earnings Preview: Catalyst Pharmaceutical (CPRX) Q1 Earnings Expected to Decline
03:47pm, Monday, 03'rd May 2021
Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CORAL GABLES, Fla., May 03, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, de
Why Is Catalyst (CPRX) Up 8.9% Since Last Earnings Report?
12:11pm, Wednesday, 14'th Apr 2021
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?
3 Magic Formula Stocks for the Value Investor
03:54pm, Sunday, 21'st Mar 2021
To increase one's chances of beating the market, one method is to select stocks that rank highly according to the "Magic Formula" criteria.
Catalyst Pharmaceuticals Inc.: Attractive Value Supported By New Growth Opportunities
04:11pm, Wednesday, 17'th Mar 2021
Catalyst Pharmaceuticals Inc.: Attractive Value Supported By New Growth Opportunities
Catalyst Pharmaceuticals, Inc. (CPRX) CEO Patrick McEnany on Q4 2020 Results - Earnings Call Transcript
02:45pm, Tuesday, 16'th Mar 2021
Catalyst Pharmaceuticals, Inc. (CPRX) CEO Patrick McEnany on Q4 2020 Results - Earnings Call Transcript
Catalyst (CPRX) Beats on Q4 Earnings, Revenues Rise Y/Y
09:06am, Tuesday, 16'th Mar 2021
Catalyst's (CPRX) earnings and revenues beat estimates in the fourth quarter of 2020.
Catalyst Pharmaceutical (CPRX) Beats Q4 Earnings and Revenue Estimates
07:17pm, Monday, 15'th Mar 2021
Catalyst (CPRX) delivered earnings and revenue surprises of 22.22% and 3.17%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update
05:26pm, Monday, 15'th Mar 2021
- Firdapse® Q4-20 Net Revenues of $31.0 Million, FY-20 Net Revenues of $119.1 Million
Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth
01:38pm, Monday, 08'th Mar 2021
Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CORAL GABLES, Fla., March 04, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing
Catalyst Pharmaceuticals Announces Support of Rare Disease Day 2021
08:03am, Monday, 22'nd Feb 2021
CORAL GABLES, Fla., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing i
